drugset / Trial / NCT00190242
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
Phase 3
Completed
99 enrolled
Assistance Publique - Hôpitaux de Paris
Ensemble contre le SIDA · collabGlaxoSmithKline · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Immunogenicity is reduced in immunocompromised patients. The aim of this prospective randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of anti-HAV vaccine in HIV-1 infected patients with CD4 count between 200 and 500 per mm3, co-infected or not with HBV and/or HCV. The factors influencing vaccine immunogenicity will be evaluate.
Timeline
- Start
- 2003-06
- Primary completion
- 2006-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Havrix | Vaccine | 1440 iu | Intramuscular |